Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer

GlobeNewswire December 14, 2021

The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults

GlobeNewswire November 23, 2021

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment

GlobeNewswire November 22, 2021

Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans

GlobeNewswire November 2, 2021

Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

GlobeNewswire October 27, 2021

Myriad Genetics Names Pamela Wong as Chief Legal Officer

GlobeNewswire October 18, 2021

Americans' anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won't seek treatment according to the GeneSight® Mental Health Monitor nationwide survey

GlobeNewswire October 11, 2021

Myriad Genetics Completes Sale of Myriad Autoimmune's Vectra Testing Business to LabCorp

GlobeNewswire September 13, 2021

Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey

GlobeNewswire September 8, 2021

Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

PR Newswire September 7, 2021

Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans

GlobeNewswire August 3, 2021

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

GlobeNewswire August 2, 2021

Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021

GlobeNewswire July 28, 2021

New research reveals most Americans can't identify the symptoms of depression

GlobeNewswire July 28, 2021

Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities

GlobeNewswire July 21, 2021

Myriad Genetics Completes Sale of Myriad RBM to IQVIA's Q2 Solutions

GlobeNewswire July 1, 2021

Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics

GlobeNewswire June 16, 2021

Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

GlobeNewswire June 4, 2021

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

GlobeNewswire June 1, 2021

IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety

PR Newswire May 27, 2021